These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Daptomycin-associated myopathy induced by concomitant administration of mirabegron. Hagiya H; Kokado R; Okuno H; Tomono K Infection; 2019 Apr; 47(2):331-332. PubMed ID: 30430398 [No Abstract] [Full Text] [Related]
4. Muscle pain associated with daptomycin. Veligandla SR; Louie KR; Malesker MA; Smith PW Ann Pharmacother; 2004 Nov; 38(11):1860-2. PubMed ID: 15367725 [TBL] [Abstract][Full Text] [Related]
5. Statins and daptomycin: safety assessment of concurrent use and evaluation of drug interaction liability. Golightly LK; Barber GR; Barron MA; Page RL Drug Metabol Drug Interact; 2013; 28(1):49-58. PubMed ID: 23314530 [TBL] [Abstract][Full Text] [Related]
6. Possible Hepatotoxicity Associated With Daptomycin: A Case Report and Literature Review. Mo Y; Nehring F; Jung AH; Housman ST J Pharm Pract; 2016 Jun; 29(3):253-6. PubMed ID: 26763341 [TBL] [Abstract][Full Text] [Related]
7. Risk of muscle toxicity events for daptomycin with and without statins: Analysis of the Japanese Adverse Event Report database. Yamada T; Mitsuboshi S; Suzuki K; Nishihara M; Uchiyama K Basic Clin Pharmacol Toxicol; 2021 Sep; 129(3):268-272. PubMed ID: 34117712 [No Abstract] [Full Text] [Related]
8. [The second life of daptomycin: analysis of a successful come-back]. Decousser JW; Doucet Populaire F Med Mal Infect; 2008 Dec; 38 Spec No 2():1-3. PubMed ID: 19185200 [No Abstract] [Full Text] [Related]
9. [Severe daptomycin-induced myopathy]. Ferrera C; Vilacosta I; Vivas D; Olmos C Med Clin (Barc); 2012 Jun; 139(3):138-9. PubMed ID: 22285497 [No Abstract] [Full Text] [Related]